Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Columns & Departments
City Had Authority Over Tree Removal on Privately Owned Streets
Features
The final print edition of New York Real Estate Law Reporter will be our January issue.
Features
News publications want to report verdicts and judgments the day they are handed down. Waiting to contact the media until after your case is decided means you've missed numerous opportunities to publicize your great work.
Features
Attorney retirement and succession planning are critical issues that are often overlooked at the management level of law firms. A key question arises: What should come first, retirement or succession planning? Although they go hand in hand, many firms avoid addressing both.
Features
On Nov. 10, 2023, Abry Partners, a leading North American middle market private equity firm, announced that it had acquired Chambers & Partners for $449 million from Inflexion, the UK private equity firm that purchased Chambers in 2018. What will this mean?
Features
It's a new year and as always, the prognosticators are prognosticating, and the forecasters are forecasting. And the predictions for 2024 are all over the place.
Features
The final print edition of Marketing the Law Firm will be our January issue.
Features
Part One of a Two-Part Article Under the current Alice framework, those attempting to patent AI innovations face an uphill battle. But, as the caselaw demonstrates, inventors and patent drafters can take steps to reduce the risk of AI patent claims being invalidated as abstract ideas.
Features
Last Term, the U.S. Supreme Court decided Jack Daniel's v. VIP Products — a case involving interaction between the Lanham Act and the First Amendment. This article traces the lower courts' reactions and applications to that decision.
Columns & Departments
Federal Circuit: PTAB Did Not Err In Finding That It Retained Authority to Issue Final Written Decision After Deadline Passed Federal Circuit: District Court Did Not Err In Finding That an Abbreviated New Drug Application Is Limited to the Uses Described Therein
